Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
COVID-19 vaccines - Are we there yet?
Australian Prescriber, Volume 44, No. 1, Year 2021
Notification
URL copied to clipboard!
Description
The novel coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, is a highly infectious human respiratory pathogen to which the global population had no prior immunity. The virus will likely continue to cause significant morbidity until there is a broadly effective vaccine. As of mid-December 2020, more than 200 COVID-19 vaccine candidates are in development and 11 have entered phase III clinical trials globally. All generate immunity to the viral spike glycoprotein. Three vaccine candidates have agreements for procurement and use in Australia if efficacy and safety requirements are met – one protein-based vaccine, one vaccine using a simian-derived adenovirus vector and one messenger RNA vaccine. The latter two vaccines have published interim analyses and efficacy results of their phase III trials. The messenger RNA vaccine is being rolled out in the UK, USA and Canada. Significant uncertainties remain. How well will some of those at highest risk of severe disease (such as older people aged >75 years and those with immunocompromising conditions) be protected by a vaccine, and for how long? Also, to what extent will vaccination protect against infection? This will determine the degree of indirect ‘herd’ protection needed through broad vaccine coverage of younger age groups. © 2021 NPS MedicineWise.
Authors & Co-Authors
Mcintyre, Peter B.
Australia, Sydney
The University of Sydney
New Zealand, Dunedin
University of Otago
Chiu, Clayton K.
Australia, Sydney
The University of Sydney
Flanagan, Katie L.
Australia, Launceston
Launceston General Hospital
Australia, Hobart
University of Tasmania
Australia, Melbourne
Rmit University
Australia, Clayton
Monash University
Macartney, Kristine K.
Australia, Sydney
The University of Sydney
Australia, Sydney
The Children's Hospital at Westmead
Statistics
Citations: 14
Authors: 4
Affiliations: 7
Identifiers
Doi:
10.18773/austprescr.2020.084
ISSN:
03128008
Research Areas
Covid
Health System And Policy
Study Design
Cross Sectional Study